Today’s episode is all about the history and future of infusing tech into healthcare with the goals of improving outcomes and lowering costs, and features one of the leading voices in this field, Jonathan Bush. Jonatha...

They say you should never judge a book by its cover, but can you judge a cell by its shape? On this episode, host Lauren Richardson is joined by Maddison Masaeli (CEO and cofounder of Deepcell), and a16z general partner ...

CAR T therapy, the groundbreaking new medicines that uses engineered T-cells to attack cancer, has been so effective in childhood leukemias that we believe it may actually be a potential cure. But this isn’t just o...

Veterinary oncology can inform human oncology, and vice versa — providing a better model for looking at drug performance, interrelationships, and more. Especially when you add in data (there’s no “doggy...

What challenges do first-time founders or tech founders encounter when building companies in the bio space, and how do they differ from traditional tech companies? In this hallway-style conversation episode of the a16z P...

It’s Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.

It’s Time to Heal is a special package about engineering the future of bio and healthcare. See more at: https://a16z.com/time-to-heal/.

Many, many pieces have been written about the immense potential of synthetic biology to make manufacturing more sustainable, flexible, and cheaper. Synthetic biology presents the tantalizing opportunity for scientists an...

1/ A thought for early-stage bio companies on the eve of the upcoming #JPM19 networking bonanza in SF: Bio entrepreneurs, especially first-time founders, often underestimate the importance of analyzing and selecting pote...

Much has been made of the looming shortage of physicians. But there’s one place where the shortage is being felt acutely, is talked about even less, and the effects will ripple far into the future: the founding of new...

Because biology is the result of evolution and not human development, bringing engineering principles to it is guaranteed to fail. Or so goes the argument behind the “Grove fallacy,” first invoked by drug industry ...

The U.S. spends over $3 trillion annually and healthcare accounts approaches 20% of our GDP — this is clearly an industry that is ripe with opportunity and lots of activity. But it is also rife with waste, operatio...

While the early signals of progress for traditional tech companies are fairly well known — product, customers, revenue — biotech companies operate under a very different timeline, metrics, and milestones. Bui...